Apollo Therapeutics

Program Leaders needed for exciting drug discovery collaboration with Oxford University! We are thrilled to announce our new drug discovery and development collaboration with Oxford University and are now seeking talented Program Leaders to join our team in Oxford. As a Program Leader, you will play a pivotal role in our drug discovery efforts. We are looking for individuals with a deep background in drug discovery who have successfully led programs through critical milestones including identifying novel drug discovery targets, validation, pharmacology and pharmacokinetics (DMPK) to identify clinical candidates. Key Responsibilities: - Engage with academic scientists to identify novel and executable drug discovery targets - Define and execute program strategy - Manage and collaborate with stakeholders across various global CROs and academic institutions to drive program success Application Process: We are partnering with Coulter Partners for the recruitment of these roles. If you are interested in exploring this opportunity please contact Apollo@CoulterPartners.com Join us in our mission to translate scientific discovery into novel therapeutics and make a significant impact. We look forward to welcoming new Program Leaders to our team.

Agreement confirmed 🤝 Oxford University and Apollo Therapeutics, a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford. Find out more ⬇️ https://lnkd.in/e6VV7YwE

Announcing a new collaboration between University of Oxford, Oxford University Innovation and Apollo Therapeutics to accelerate drug discovery and development from world class research 👇 Find out more: https://lnkd.in/efTUaWGX Science and Technology Secretary Peter Kyle said: “We want to harness life sciences to transform the UK’s healthcare and drive economic growth. Together, Apollo and Oxford University could deliver new medicines to help us tackle cancer, autoimmune disease, and more, improving and saving thousands of lives. “The life sciences sector is open for business under this Government. We know that the best and boldest breakthroughs happen when industry and academia join forces, backed by government, and this partnership between Apollo and Oxford is proof of exactly what can be unlocked, when we open the doors to collaboration.” #pharmaceuticals #drugdiscovery #translationalresearch #medicines #drugdevelopment | Department for Science, Innovation and Technology | Nuffield Department of Medicine | Nuffield Department of Primary Care Health Sciences - University of Oxford | Department of Oncology, University of Oxford | Dunn School, University of Oxford

Delighted to announce that we have entered into a new drug discovery and development collaboration with the University of Oxford.   The collaboration will see teams from Apollo and the University of Oxford working together to identify and assess the potential of novel validated therapeutic targets, bringing Apollo’s in-house expertise and resources to Oxford’s world class researchers and delivering faster routes to market for new medicines.   The partnership marks our sixth collaboration with a world leading university, further bolstering our scalable R&D platform, and supporting our aim to translate breakthroughs in biology and basic medical research into innovative new medicines.    Read the full press release on our website here: https://lnkd.in/eH95J4c5   #UKscience #Collaboration #UniversityofOxford

Happy Birthday to us! This weekend it was the anniversary of our first financing, where we raised $145m to support our pipeline development. Just three years later, our team is made up of more than 50 people across the UK and US, over 20 active therapeutic programs, five of which are in development, and we have raised over $450m to date. It’s amazing to see how far we’ve come, and we look forward to seeing what we can achieve in the future. #biotech #fundraising #science 

Apollo Therapeutics will be at the Jefferies Global Healthcare Conference in New York City. Our CEO Richard Mason, will be hosting one-on-one meetings on Tuesday, June 4, which can be booked via Jefferies, or alternatively, please do let us know directly if you would like to connect at the conference. We look forward to seeing you there! #JefferiesHealthcare #investor #conference

Apollo Therapeutics will be at the Jefferies Global Healthcare Conference in New York City. Our CEO Richard Mason, will be hosting one-on-one meetings on Tuesday, June 4, which can be booked via Jefferies, or alternatively, please do let us know directly if you would like to connect at the conference. We look forward to seeing you there! #JefferiesHealthcare #investor #conference

We are delighted to see that our partner King's College London has been awarded funding by Research England to create the UK Smart Trials Development Hub, a unique research facility to accelerate the understanding of disease biology and enable the development of precision therapeutics to treat individual patients.   At Apollo Therapeutics, we are excited to support this development, which will improve our ability to develop novel therapeutics through the analysis of individual patient data to create ‘digital biological twins’, enabling the understanding of each patient's unique characteristics and improved and individualised treatment paradigms.   #biotech #partnernews #biology

Our CEO Richard Mason will be presenting an overview of Apollo Therapeutics at the Evercore ISI 2024 Emerging Biotech Conference tomorrow (Thursday, February 29) at 10:45 – 11:15 ET. #biotech #conference

Apollo Therapeutics will be attending the Cowen Inc. 44th Annual Health Care Conference in Boston, US next week from March 4-6. Our CEO Richard Mason and CFO Jamie Heath will be hosting one-on-one meetings on Tuesday, March 5 - meeting slots can be booked via Cowen or please do let us know directly if you would like to connect at the conference.   We look forward to seeing you there!  #biotech #conference